Overall survivalis shown for all patients treated with bosutinib at a median follow-up of 28.5 months. IM indicates imatinib; DAS, dasatinib; and NI, nilotinib. *Includes 3 patients who previously received all 3 inhibitors and 1 patient with NI intolerance. †Overall survival rates at 1 and 2 years were based on Kaplan-Meier estimates.